A phase 2 study of single agent ibrutinib for first‐line treatment of chronic graft‐versus‐host disease: A new paradigm and lessons learned is a dataset published in British Journal of Haematology (2025). On theSindex it has a DataRank of 0.104, placing it in the top 77.8% of the data-sharing corpus. It has been cited 1 time.
Ranks in the top 78% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Intramural NIH HHS
Grant: Z01 SC006537
Intramural NIH HHS
Grant: Z01 BC010627
Intramural NIH HHS
Grant: Z01 SC006536
Intramural NIH HHS
Grant: Z01 BC010548
This work was supported by funding from the Intramural Research Program, National Institutes of Health, Center for Cancer Research, National Cancer Institute, Center for Cancer Research, also through a Collaborative Research Agreement between Pharmacyclics and the Center for Cancer Research.
Fields of Study
Keywords